Evercore ISI Upgrades Imperva (IMPV) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Needham & Company Cuts Price Target on Imperva (IMPV) Following 3Q
November 4, 2016 8:21 AM EDTNeedham & Company maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $43.00 (from $64.00), following the company's 3Q earnings report. After the material guide-down last quarter, the results for IMPV were a solid beat, with $68.4m and $0.08 EPS well above $63.2m and ($0.16) loss per share consensus. CY16 was... More
DA Davidson Upgrades Imperva (IMPV) to Buy
November 4, 2016 7:14 AM EDTDA Davidson upgraded Imperva (NYSE: IMPV) from Neutral to Buy.
For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.
Shares of Imperva closed at $35.10 yesterday.
... MoreImperva (IMPV) Tops Q3 EPS by 24c, Plans to Remain Standalone Compnay
November 3, 2016 4:44 PM EDTImperva (NYSE: IMPV) reported Q3 EPS of $0.08, $0.24 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $63.1 million.
GUIDANCE:
Imperva sees FY2016 EPS of ($0.38)-($0.35), versus the consensus of ($0.80). Imperva sees FY2016 revenue of $255.1-257.1 million, versus the consensus of $250.2 million.
Conclusion of Strategic Alternatives Review Process
Imperva announced today that its Board of Directors has concluded its previously announced review of strategic alternatives to enhance... More
